Evidence map›Paper›PMID 36692418›Full record

Observational studyJournal of the Chinese Medical Association : JCMA2023

Health-related quality of life improvement by adalimumab therapy in patients with rheumatoid arthritis in Taiwan: A nationwide prospective study.

Song-Chou Hsieh, Ping-Han Tsai, Chang-Fu Kuo, Tien-Tsai Cheng, Ning-Sheng Lai, Jing-Chi Lin, Liang-Hung Lin, Chang-Youh Tsai

Registry-linked trialOpen access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of the Chinese Medical Association : JCMA, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02616380 (Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02616380 completednot on this map

Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan

TypeobservationalSponsorAbbVieRan2015 to 2017Enrolled100ConditionsRheumatoid Arthritis
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

Song-Chou HsiehDivision of Rheumatology, Immunology & Allergy, Department of Medicine, National Taiwan University Hospital, Taipei, Taiwan, ROC.
Ping-Han TsaiDivision of Rheumatology, Allergy and Immunology, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung Medical Foundation), New Taipei City, Taiwan, ROC.
Chang-Fu KuoDivision of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC.
Tien-Tsai ChengDivision of Rheumatology, Allergy, and Immunology, Chang Gung University and Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, ROC.
Ning-Sheng LaiDivision of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, ROC.
Jing-Chi LinDivision of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan, ROC.
Liang-Hung LinDivision of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan, ROC.
Chang-Youh TsaiDivision of Immunology and Rheumatology, Department of Medicine, Fu Jen Catholic University Hospital, New Taipei City, Taiwan, ROC.
Chang Gung Memorial Hospital · TWChiayi Chang Gung Memorial Hospital · TWFu Jen Catholic University · TWKaohsiung Chang Gung Memorial Hospital · TWLinkou Chang Gung Memorial Hospital · TWNational Taiwan University Hospital · TWTaipei Tzu Chi Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo determine the effects of adalimumab on health-related quality of life (HRQoL) in Taiwanese patients with moderate-to-severe rheumatoid arthritis (RA) (NCT02616380).

methodsDuring a 24-week observational period, 100 biologic-naive patients with RA received 40 mg adalimumab subcutaneously, every 2 weeks. The primary endpoint was a change in Health Assessment Questionnaire-Disability Index (HAQ-DI) score at 24 weeks. The secondary endpoints included change in HAQ-DI at week 12, number and percentage of patients achieving a meaningful improvement in HAQ-DI at weeks 12 and 24, and changes in the 36-Item Short Form Health Survey (SF-36), EuroQol 5-dimension 3-level version (EQ-5D-3L) index, and Work Productivity and Activity Impairment (WPAI) questionnaire scores at weeks 12 and 24.

resultsAt weeks 12 and 24, mean changes in HAQ-DI from baseline were -0.34 ± 0.46 and -0.44 ± 0.59 (both p < 0.001), and clinically meaningful improvement in HAQ-DI was achieved by 60.4% and 59.6% of patients, respectively. SF-36, EQ-5D-3L index, and WPAI scores significantly improved ( p < 0.001) from baseline to weeks 12 and 24. Exploratory analyses showed diabetes was significantly associated with changes in HAQ-DI, EQ-5D-3L, and WPAI scores whereas peptic ulcer correlated with changes in the SF-36 physical component summary T-score.

conclusionHRQoL improved after initiation of adalimumab therapy in Taiwanese patients with moderate-to-severe RA.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidAdalimumabHumansProspective StudiesQuality of LifeSeverity of Illness IndexTaiwanTreatment OutcomeAdalimumabAntirheumatic Agents

Identifiers

PMID36692418
PMCPMC12755651
OpenAlexW4317866070

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.